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1The Two Faces of 
Influenza
Annual, epidemic Influenza and
Pandemic Influenza
Sabine Arnoux March 2007, Eldoret, Kenya
2Often misunderstood and underestimated, 
Influenza is not just “a bad cold”!
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4Influenza virus mutations 
Influenza type A viruses mutate frequently, 
type B viruses mutate less frequently, 
Mutation enables the virus to bypass the population’s acquired 
immunity
Both the haemagglutinin and neuramidase surface antigens mutate
Mutation occur through two mechanisms
Antigenic drift  
Occurs continually
Leads to modified viruses that causes annual epidemics
Antigenic shift
Occurs rarely
Leads to novel viruses that cause pandemics
Betts FR, Douglas RG, Mandell G.L., 
Douglas R. G., Bennett J.E., Principles 
and practice of infectious diseases, 3rd 
ed., 1990;39:1306-25
5Variations within a 
subtype
Mutation
RNA segment
Coding for HA or NA Amino 
acid 
change(s)
driftA/H3N2
Mutation(s)
Antigenic drift 
Minor variations in the Haemagglutinin and/or Neuramidase
Affects Influenza type A and B viruses
Caused by mutations in the viral RNA
Occurs each year within a subtype
The resulting modified viruses cause annual epidemics
6Genetic  reassortment
Host cell
Novel
virus
Genetic reassortment: 
Hybrid strain
New strain with new HA and/or NA
Human strain
Avian strain
Antigenic shift 
Antigenic shift
Emergence of a novel virus
Only affects type A viruses
Caused by major genetic modifications to the HA or NA
The human population has little or no immune protection against the 
novel virus…
…which leads to pandemics every 10 to 40 years
7Transmission
Virus is mainly spread through 
the air by coughing and sneezing, 
especially in closed public 
places: public transport, meeting 
rooms, ... 
An infected person can transmit 
the virus to others from 1-2 days 
before flu symptoms start, and 
for 5 days afterwards
8During each annual winter epidemic:
5 to 10 % of the world’s population catches influenza 
i.e., 500 million people
Including 3 to 5 million serious cases
100 000 to 1 000 000 deaths each year
Influenza does not discriminate: 
it affects men and women, boys and girls of all ages, in all 
sectors of the population, and in all countries
9Typical influenza illness
Complications
Sore throat,  Myalgia
Headache
Cough
Malaise, prostration
Corzya 
(blocked/runny nose)
Onset of illness
Incubation 
period
T
e
m
p
e
r
a
tu
r
e
 (
C
)
Time (in days)
37
39
41
0
1
2
3
4
5
0 1 2 3 4 5 6 7 8 9 10
L
O
G
1
0
v
ir
u
s
ti
tr
e
In
n
a
s
o
p
h
a
ry
n
x
Virus
Fever
Infectious 
period
10
Complications
Mainly affect the elderly and infants
Infants
Otitis, either viral or a secondary bacterial infection
Exacerbation of chronic asthma
More rarely: high fever and convulsions
Myositis
Adults
Bronchitis, sinusitis
Fulminant viral pneumonia (seen during influenza pandemics)
Elderly persons and those with high-risk chronic medical conditions
Acute bronchitis
Pneumonia: viral or bacterial secondary infection
Respiratory (asthma), cardiac, renal or metabolic (diabetes) 
decompensation
Treanor JJ. Orthomyxoviridae: Influenza virus. In: 
Mandell GL, Bennette JE, Dolin R, editors. 
Principles and practice of infectious diseases. 
London: Churchill Livingstone, 2004: 1823-1849.
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Influenza in at risk 
patients
Asthmatics
Diabetics
At risk patients
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Association of 
respiratory viral 
infections with 
asthmatic crisis 
in adults
138 adults with 
asthma
10/90 to 08/92, UK
> 40% of symptomatic asthmatic crisis were 
assiciated with viral respiratory infections 
71% of the crisis were associated with cold 
symptoms
Influenza was associated with severe crisis
Does flu 
vaccination 
induce crisis in 
asthmatics?? 
12,000 patients  65-
79 years old with 
asthma and COPD, 3 
flu seasons 
Asthma diagnosis as well as corticosteroid 
prescriptions are the same after vaccination 
and during low risk season
Asthmatic crisis  do not increase significantly 
after vaccination
Nicholson et al., BMJ, 1993
Tata et al., Thorax, 2003 
Influenza vaccination does not induce asthma crisis in adults
Influenza is a severe disease for asthmatics
1
2
Influenza in asthmatic patients
13
349 asthmatic 
children
0-12 years
2 influenza 
seasons
27% reduction in   acute respiratory attacks
56% reduction during first influenza season 
Smits et al., Epidemiol Infect, 2002 
Flu vaccination prevents asthma crisis
All children
55% reduction in acute respiratory attacks
77% reduction during second influenza season
Children < 6 years
130.000 
asthmatic 
children
1-6 years
3 seasons 
(USA)
Kramarz et al., J Pediatr, 2001 
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Influenza risks in diabetics
Diabetics are
6 times more at risk to be 
hospitalized with an influenza 
diagnosis
3 times more at risk of dying of 
pneumonia or influenza
Mortality rate increases by  5 to 
15% during influenza epidemics
CFR for influenza: 12%
Immune response
Response is satisfactory in 70% of 
patients
Patients who don’t respond to initial 
immunization respond to a second 
dose
Influenza consequences in 
diabetics are very severe
Immunization is very 
valuable in these patients
15
Effectiveness of influenza vaccination in 
diabetic patients
2
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In a case control study, influenza vaccination 
reduced hospitalization:
•For pneumonia and influenza by 80%
•For bronchitis
•For diabetis without mention to any 
complication
•For diabetic comas
•For acidocetosisEffectiveness of influenza 
vaccination in the reduction of the 
risk of hospitalization for influenza 
or pneumonia, or death
50% in 1996-7
21% in 1997-8
Influenza vaccination was 
EFFECTIVE since it reduced 
hospitalizations during influenza 
epidemics
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Influenza and cardiovascular diseases (CVD)
•In 2002, CVD represented 29.2%
(16.7 millions) of worldwide deaths
•Global CVD impact increases 
(increase in population age, 
urbanization) 
1998                1999                  2000                 2001
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Flu activity and hospital admissions for heart failure
In people older than 65 years, Hong Kong, 1998-2001
Obvious superposition between the flu 
activity peak and heart failure 
hospitalizations
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Benefits of flu vaccination in patients with 
CVD
FLUVACS study (Argentina): flu vaccination and reduction of 
death  and ischemic events in patients with Myocardial 
infarction
Significant reduction in deaths (75%) and rehospitalizations
Reduction of the triple risk (CV deaths, infarction and severe 
ischemia)
Consistant results during 2 years, and with other studies
Four case control studies: reduction of:
49% for primary cardiac arrest risk
67% for the MI risk
55% for cerebral stroke (2 studies)
CONCLUSION: Flu vaccination is associated with a reduction in the 
risk of CV events
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Groups at increased risk for Influenza-
related complications 
Persons at high risk for influenza-related complications and severe 
disease, including 
Children aged 6--59 months, 
Pregnant women, 
Persons aged >50 years, 
Persons of any age with certain chronic medical conditions; and 
Persons who live with or care for persons at high risk, including
Household contacts who have frequent contact with persons at high 
risk and who can transmit influenza to those persons at high risk and
Health-care workers. 
Influenza vaccination is the primary method for preventing influenza and its 
severe complications. 
The Advisory Committee on Immunization Practices (ACIP) recommends 
annual influenza vaccination for the following groups:
(1). CDC. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR July 29, 2006;54: RR8.
19
Influenza: vaccine, 
vaccine production
20
Influenza vaccines
Influenza vaccines first available in the 1940s
Whole virion vaccines: Connaught Laboratories (USA) in 1947 and 
Institut Mérieux (France) in 1968
Today’s vaccines
Trivalent 
2 subtype A strains (H1N1, H3N2) 
1 type B strain
Two formulations per year: one for each hemisphere
The WHO recommends the viral composition of each formulation, based on the 
predominant circulating strains
Different types of vaccines are available
Inactivated, injectable (split virion, sub-unit and a few whole virion vaccines)
Live attenuated vaccine for nasal administration
Vaccine viral strains grown in embryonated chicken eggs
Cell culture-based vaccines are in development
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Influenza Vaccination: 
The best defence against illness for more than 50 
years
Effective
Vaccination mimics natural infection, providing protection for 6-12 
months against the vaccine strains
Protects 70–90% of vaccinated healthy adults 
Reduces complications and mortality by 70--85% in elderly 
persons
Beneficial to society
Vaccination reduces the risk of transmitting the virus to others: 
Persons at risk of complications of influenza infection (the elderly, infants…) 
Family, friends, colleagues…
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International surveillance network
Choice of vaccine strains procedure
Hannoun C. Role of international networks for the surveillance of influenza. Eur Journal of Epidemiol 1994;10:459-61
Sentinel Doctors  Isolation of strains
National influenza Centers
(over 110 national laboratories in over 80 countries)
World Health Organization
(WHO - Geneva)
Collaborating Reference Centers for 
Research against influenza
(London, Atlanta, Tokyo and Melbourne)
Vaccine Manufacturers
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 Around 300 million doses produced yearly worldwide  in 2004
 Influenza vaccine-producing countries:
Europe (UK, France, Germany, Italy, Netherlands), Canada, USA, Japan, 
Australia
12% of world population with 95% of global vaccine production
Production capacity of European countries: 190 million doses (65%)
 International Area (outside US, Western Europe, Canada, Australia & Japan): 85 
M doses
97% of these doses are produced in Europe
Most countries in the world depend on European 
vaccines
24
Current influenza immunization rates 
are very different around the world
(17) Fedson DS. The macroepidemiology of influenza vaccination in 56 
countries, 1997-2003: a report from the macroepidemiology  of 
influenza vaccination (MIV)
Study Group. Vaccine, 2005, In Press, Uncorrrected Proof.
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Source: International Influenza Vaccine Supply Task Force 2004
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Inter-Pandemic Years: 
Global Influenza Vaccine Distribution 
1994 – 2003
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Influenza vaccine 
Manufacturing time-table
INTERNATIONAL SURVEILLANCE NETWORK
VACCINE MANUFACTURER
M A M J J A S O N D J FF
WHO
(Northern hemisphere)
WHO
(Southern hemisphere)
M
PRODUCTION
PRODUCTION
Choice of strains Vaccine  on the market
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D0  - 6 
months
Egg supply organisation 
Monovalent batches
July/August
Blending
Mid 
May
Filling / Packaging
Pharmaceutical file
Clinical
trial Vaccine 
Delivery
Seed lots
Egg supply for production
WHO meeting
D0 = mid Feb
Reagent 
availability
End of May
Ref Member 
State ReleaseMA
D0
Packaging documentation
Influenza vaccines:
Manufacturing timetable
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The threat of 
Pandemics
29
What is pandemic influenza?
An exceptional epidemiological event:
Rapid worldwide circulation of a highly contagious virus 
New subtype of an influenza type A virus against which 
humans have little or no immunological protection
Higher morbidity and mortality than seen with classical annual 
influenza
Previous pandemics affected 25–50% of the world population 
over a 13–23 month period 
Young, healthy adults are affected by severe forms of the  
disease
30
412 BC
1918
1933
1957
1968
Asian flu H2N2
Hong Kong flu H3N2
Influenza virus isolated for the first time
Spanish flu H1N1
Epidemic 
reported 
by 
Hippocrates
1173-1174 Influenza-like epidemics first reported
Potter CW. A history of influenza. J Appl Microbiol 2001; 91(4):572-579.
1889 
& 1891
H3N8 pandemic
Influenza pandemics in history
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Spanish influenza (A/H1N1)
1918 - 1919
1 billion people affected 
(25-30% of the world population)
3 epidemic waves:
March and September 1918 
February 1919
Exceptionally virulent strain
40-50 Million deaths:
> 200 000 in France
500 000 in the USA
1.5-2 Million in Africa
7-10 Million in India
32
Asian influenza (A/H2N2)
1957 - 1958
2 waves:
Children
Elderly persons
1-2 million deaths worldwide
Improved surveillance and 
warning compared to 1918-19 
(WHO)
Vaccines and antibiotics available
Milder pandemic
33
Hong Kong influenza (A/H3N2)
1968 -1969
Same Asian origin as 
1957-58 pandemic
Milder pandemic (possible 
cross-protection provided by 
exposure to the 1957 H2N2 
strain)
0.8-1 Million deaths worldwide
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Influenza Pandemic - Definition
3 conditions for a pandemic
Emergence of a new influenza A virus with a different HA from those of 
recently circulating strains
Absence of immunity in the population
against the new strain
New virus with high virulence and rapid person to person transmission
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Mechanisms of emergence of novel human 
viruses
Adaptive mutation  (e.g., Spanish flu) 
The virus becomes fully adapted to humans through serial genetic 
modifications during successive infection in humans and other mammals
Gene reassortment from 2 viruses co-infecting a host (e.g., Asian 
flu)
Strain re-emergence (e.g., Asian flu: H2N2)
Human Virus
Avian Virus
Genetic 
reassortment
Hybridization
Novel, mutant 
influenza virus
Rearrangement of 
the genome
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Wild birds are the 
influenza A viral 
reservoir
HA NA
Nicholson KG, et al. 
Lancet 2003; 362: 1733.
Influenza’s main 
other natural 
hosts:
Poultry,
Horses,
Swines,
Humans
Fouchier RA, Osterhaus AD, Brown IH. 
Animal influenza virus surveillance. 
Vaccine 2003; 21(16):1754-1757
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Cumulative Number of Confirmed Human Cases of 
Avian Influenza A/(H5N1) Reported to WHO
27 February 2007  
2003 2004 2005 2006 2007 Total Country 
  cases deaths cases deaths cases deaths cases deaths cases deaths cases deaths 
Azerbaijan 0 0 0 0 0 0 8 5 0 0 8 5 
Cambodia 0 0 0 0 4 4 2 2 0 0 6 6 
China 1 1 0 0 8 5 13 8 0 0 22 14 
Djibouti 0 0 0 0 0 0 1 0 0 0 1 0 
Egypt 0 0 0 0 0 0 18 10 4 3 22 13 
Indonesia 0 0 0 0 19 12 56 46 6 5 81 63 
Iraq 0 0 0 0 0 0 3 2 0 0 3 2 
Lao People's Democratic 
Republic 
0 0 0 0 0 0 0 0 2 1 2 1 
Nigeria 0 0 0 0 0 0 0 0 1 1 1 1 
Thailand 0 0 17 12 5 2 3 3 0 0 25 17 
Turkey 0 0 0 0 0 0 12 4 0 0 12 4 
Viet Nam 3 3 29 20 61 19 0 0 0 0 93 42 
Total 4 4 46 32 97 42 116 80 12 9 276 168 
Total number of cases includes number of deaths. 
WHO reports only laboratory-confirmed cases.  
All dates refer to onset of illness. 
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Avian influenza epidemics caused by highly 
pathogenic virus (HPV) H5N1
1959: first epidemics documented in 
chickens
1997 in  Hong Kong
1.5 Million chickens culled
18 human cases
6 deaths
Since December 2003
The H5N1 HPV progressively spread
From Thailand, Vietnam and Cambodia, to 
Laos, South Korea, China, Indonesia, 
Malaysia, and in 2005 to Mongolia and 
Kazakhs…etc
>140 Million chickens culled
To date (end feb 2007): 276 human 
cases, including 168 deaths
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Current status of avian H5N1 epidemic
The epidemic is now endemic in the chickens of several Asian 
countries
Highly Pathogenic Avian Influenza Virus H5N1 has been also 
isolated from certain species of migrating birds
Ducks can carry the virus, 
but most of them do not develop the disease
In addition to humans,
the virus has infected other mammals (felines, ferrets, pigs, New 
Zealand white rabbit, cynovolgus macchaque…etc)
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Necessary conditions for the emergence of a 
pandemic influenza virus
I. Emergence of a influenza A virus against which humans have 
little or no protective immunity 
II. The new virus is able to infect and grow in humans, causing 
severe disease (virulence)  From December 2003 to Feb 2007,
276 persons were infected (168 deaths) in 12 countries 
III. The new virus is easily and quickly spread from human to 
human, causing a continuous chain of infection 
(contagiousness) to date, human-to-human transmission is not 
confirmed with this virus
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World pandemic 
preparedness 
43
It is impossible to predict when the next pandemic will occur
WHO Weekly Epidemiological Record, November 2002:
„inevitable shortage of vaccines and antivirals“
Worldwide production of influenza vaccines is currently able 
to cover less than 5% of the world s population.
In case of a pandemic:
severe pressure on health services, 
social disruption, 
interruption of commerce, economic losses, etc.
Influenza Pandemic
Why do we need planning?
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Preparedness plans of WHO, governments 
and private sector follows the WHO phases
WHO Phases
Interpandemic period
Phase 1 No new flu virus circulating in humans
Phase 2 No new flu virus circulating in humans, but an animal virus poses a substantial risk of
human disease.
Pandemic alert period (pre-pandemic)
Phase 3 Human infection with a new virus (no person-to-person transmission, or rare and isolated
cases connected to close contact)
Phase 4 Clusters of limited and localized person-to-person transmission (virus incompletely
adapted to humans)
Phase 5 Expansion of clusters, still geographically localized (the virus is adapting to humans)
Pandemic period
Phase 6 Significant person-to-person transmission in the population, with rapid geographic
expansion
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17 priority activities organized around 4 main objectives
Strengthening
surveillance
Improving
knowledge
of disease burden
Increasing
vaccine usage
Accelerating
pandemic
preparedness
WHO Global Agenda on Influenza Surveillance 
and Control
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Essential service providers
incl. health care personnel, firemen, police, persons involved 
in water, gas and electricity distribution, etc.
Groups at high risk of death and severe complications
Persons without risk factors for complications
Healthy adults and children
Each country will need to define its priority groups
„The final choice is a political one“ (Chippaux, 1994)
Priority groups for vaccination
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Pandemic threat is a major driver for Interpandemic 
coverage extension
To increase production capacities
To avoid genetic reassortment
Resolution of the World Health Assembly, May 2003
„Better use of influenza vaccines for seasonal epidemics will 
help to ensure that manufacturing capacity meets demand in a 
future pandemic, as well as preventing numerous deaths“
Pandemic preparedness and use of influenza 
vaccines in Interpandemic periods
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Preparedness activities are in line with the 
WHO warnings and preparedness guidelines
1. Pandemic influenza is different from avian influenza
2. Influenza pandemics are recurring events
3. The world may be on the brink of another pandemic
4. All countries will be affected
5. Widespread illness will occur
6. Medical supplies will be inadequate
7. Large numbers of deaths will occur
8. Economic and social disruption will be great
9. Every country must be prepared
10. WHO will alert the world when the pandemic threat increases
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Thank you !
